πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 6 of 18

  1. US 11666658

    Rifamycin analogs and antibody-drug conjugates thereof

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11655291

    Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11655286

    Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11649273

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11642390

    Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11640848

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11634480

    Human antibodies to GREM1

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11633501

    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11629195

    Anti-IL2 receptor gamma antigen-binding proteins

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11622547

    Genetically modified mouse that expresses human albumin

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11608380

    Anti-EGFRvIII antibodies and uses thereof

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11608381

    Methods of treatment using a leptin receptor agonist antibody

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11603413

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11603408

    Methods for treating skin infection by administering an IL-4R antagonist

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11603407

    Stable antibody formulation

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11596635

    Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11596690

    Stabilized formulations containing anti-IL-33 antibodies

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11590223

    Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11594302

    High resolution allele identification

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11584966

    Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11579150

    Methods for characterizing disulfide bonds

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11578135

    Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11578127

    Anti-Fc epsilon-R1 alpha (FcΞ΅R1Ξ±) antibodies, bispecific antigen-binding molecules that bind FcΞ΅R1Ξ± and CD3, and uses thereof

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11576984

    Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11576356

    Genetically modified non-human animals and methods of use thereof

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11571636

    Methods for quantitating individual antibodies from a mixture

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11571482

    Human antibodies to S. aureus Hemolysin A toxin

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11559564

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11559489

    Tuning of release kinetics in hydrogels

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11559576

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11548932

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11548947

    Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11547101

    Non-human animals having a disruption in a C9ORF72 locus

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11542326

    Anti-IL-25 antibodies and uses thereof

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11542317

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11535663

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11535675

    Antigen-binding proteins that antagonize leptin receptor

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11530255

    Human antibodies to Ebola virus glycoprotein

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11525629

    Target residual moisture content for lyophilized drug product

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11525001

    Anti-CD8 antibodies and uses thereof

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11519020

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11518804

    Method of treating osteoarthritis with an antibody to NGF

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11512309

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11511001

    Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11504426

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11505593

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11504390

    Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11505594

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.